best of hcv from aasld 2013
DESCRIPTION
Best of HCV From AASLD 2013. Paul Kwo , MD Indianapolis, Indiana, USA. This activity has been supported by an independent medical education grant from Bristol Myers Squibb. - PowerPoint PPT PresentationTRANSCRIPT
1
Best of HCVFrom AASLD 2013
This activity has been supported by an independent medical education grant from Bristol Myers Squibb.
2013 IC-HEP Educational supporters include Bristol Myers Squibb and Janssen Therapeutics EMEA. Supporters do not influence IC-HEP faculty selection or educational content.
Paul Kwo, MDIndianapolis, Indiana, USA
2
Abstract #LB-1
Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve
patients with chronic HCV genotype 1 infection
Gregory T. Everson1, Karen D. Sims2, Paul J. Thuluvath3, Eric Lawitz4, Tarek Hassanein5,Maribel Rodriguez-Torres6, Trevor Hawkins7, Howard Schwartz8, Vinod K. Rustgi9, Federico Hinestrosa10,
James M. Levin11, Zobair M. Younossi12, Lynn R. Webster13, Timothy Eley2, Shu-Pang Huang14,Fiona McPhee15, Dennis M. Grasela2, David F. Gardiner2
1. University of Colorado Denver, Aurora, CO, United States. 2. Bristol-Myers Squibb, Hopewell, NJ, United States. 3. Mercy Medical Center, Baltimore, MD, United States. 4. The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States. 5. Southern California Liver Centers, Coronado, CA, United States. 6. Fundación de Investigación, San Juan, Puerto Rico,United States. 7. Southwest CARE Center, Santa Fe, NM, United States. 8. Miami Research Associates, South Miami, FL, United States.
9. Metropolitan Research, Arlington, VA, United States. 10. Orlando Immunology Center, Orlando, FL, United States. 11. Dean Foundation for Health, Research and Education, Inc, Madison, WI, United States. 12. Inova Fairfax Hospital, Center for Liver Diseases,Falls Church, VA, United States. 13. CRI Lifetree, Salt Lake City, UT, United States. 14. Bristol-Myers Squibb, Princeton, NJ, United States. 15. Bristol-Myers Squibb, Wallingford, CT, United States.
3
• Daclatasvir (DCV)– NS5A replication complex inhibitor with potent, pan-genotypic activity in
vitro– Studied in over 5500 patients
• Asunaprevir (ASV)– NS3 protease inhibitor active against genotypes (GT) 1, 4, 5, and 6 in vitro– Studied in over 2000 patients
• BMS-791325– Non-nucleoside, NS5B polymerase inhibitor active against GT 1, 3, 4, 5,
and 6 in vitro– Studied in over 500 patients
Direct-Acting Antiviral Agents
Everson GT, et al. Abstract #LB-1, AASLD 2013
4
Randomized, Phase 2b Open-Label Study (AI443-014)
• Patients: treatment-naive, stratified by GT 1a/1b and presence of biopsy-confirmed cirrhosis (82% GT1a and 9% cirrhotics).
• Primary end point: HCV RNA < LLOQ 12 weeks post-treatment (SVR12)
– Observed analysis: breakthrough, relapse, addition of pegIFNα/RBV = failure
– Modified intent-to-treat analysis: missing, breakthrough, relapse or addition of pegIFNα/RBV = failureEverson GT, et al. Abstract #LB-1, AASLD 2013
DCV 30 mg BID + ASV 200 mg BID + BMS-791325 75 mg BID
DCV 30 mg BID + ASV 200 mg BID + BMS-791325 150 mg BID
12-week follow-upAdditional
follow-up to SVR48
0 12 24
N = 80
N = 86
Week
Primary endpoint: SVR12
5
Efficacy Through SVR12 (Observed)
Series10
20
40
60
80
100
End of Treatment SVR4 SVR12
Res
pons
e, %
of p
atie
nts
DCV + ASV + ‘325 75 mg
DCV + ASV + ‘325 150 mg
97.5 94.2 92.4 91.7 92.2 91.7
78/80 81/86 73/79 77/84 71/77 77/84
Everson GT, et al. Abstract #LB-1, AASLD 2013
6
Event, n (%)
DCV + ASV + ‘325 75 mg
N = 80
DCV + ASV + ‘325 150 mg
N = 86Total
N = 166Serious AEs 1 (1.3) 2 (2.3) 3 (1.6)AEs leading to discontinuation 1 (1.3) 1 (1.2) 2 (1.1)Grade 3/4 AEs 0 1 (1.2) 1 (0.5)Most frequent on-treatment AEs (≥ 10%)
Headache 17 (21.3) 24 (27.9) 41 (24.7)Diarrhea 12 (15.0) 13 (15.1) 25 (15.1)Fatigue 12 (15.0) 7 (8.1) 19 (11.4)Nausea 10 (12.5) 7 (8.1) 17 (10.2)
Grade 3/4 lab abnormalitiesAspartate aminotransferase (AST) 1 (1.3) 0 1 (0.5)Glucose, fasting serum (high) 1 (1.3) 1 (1.2) 2 (1.2)Phosphorus, inorganic 0 1 (1.2) 1 (0.5)Bilirubin, total 0 1 (1.2) 1 (0.5)
Safety Outcomes
Everson GT, et al. Abstract #LB-1, AASLD 2013
7
Abstract #211
All-oral Combination of Daclatasvir Plus Asunaprevir in Interferon Ineligible Naive/Intolerant and Nonresponder
Japanese Patients Chronically Infected with HCV Genotype 1b: Results from a Phase 3 Trial
Kazuaki Chayama1, Yoshiyuki Suzuki2, Kenji Ikeda2, Joji Toyota3, Yoshiyasu Karino3, Yoshiiku Kawakami1, Akio Ido4, Kazuhide Yamamoto5, Koichi Takaguchi6, Namiki Izumi7, Kazuhiko Koike8, Tetsuo Takehara9, Norifumi Kawada10, Michio Sata11, Hidetaka
Miyagoshi12, Timothy Eley13, Fiona McPhee13, Wenhua Hu13, Hiroki Ishikawa12, Eric A. Hughes13, Hiromitsu Kumada2
1. Hiroshima University, Hiroshima, Japan. 2. Toranomon Hospital, Tokyo, Japan. 3. Sapporo-Kousei General Hospital, Sapporo, Japan. 4. Kagoshima University, Kagoshima, Japan. 5. Okayama University, Okayama, Japan. 6. Kagawa Prefectural Hospital, Kagawa, Japan.7. Musashino Red Cross Hospital, Tokyo, Japan.
8. University of Tokyo, Tokyo, Japan. 9. Osaka University, Osaka, Japan. 10. Osaka City University, Osaka, Japan. 11. Kurume University, Fukuoka, Japan. 12. Bristol-Myers KK, Tokyo, Japan. 13. Bristol-Myers Squibb, Princeton, NJ, United States.
8
HCV RNA < LLOQ, n (%) Ineligible naïve/Intolerant
(IN/I) Patients n = 135a
Nonresponder (NR) Patients n = 87b
Total N = 222
RVR, Week 4 114 (84.4) 53 (60.9) 167 (75.2)
cEVR, Week 12 125 (92.6) 77 (88.5) 202 (91.0)
SVR4 126 (93.3) 71 (81.6) 197 (88.7)
SVR12 120 (88.9) 70 (80.5) 190 (85.6)
SVR24 118 (87.4) 70 (80.5) 188 (84.7)
Virologic Response
aIneligible naïve: n=100; Intolerant: n=35 bNull responders: n=48; Partial responders: n=36; Undetermined: n=3
Chayama K, et al. Abstract #211, AASLD 2013
9
Abstract #LB-3
SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic
HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study
Ira M. Jacobson1, Reem H. Ghalib2, Maribel Rodriguez-Torres3, Zobair M. Younossi4, Ana Corregidor5, Mark S. Sulkowski6, Edwin DeJesus7, Brian Pearlman8, Mordechai Rabinovitz9, Norman Gitlin10, Joseph K. Lim11,
Paul J. Pockros12, Bart Fevery13, Tom Lambrecht14, Sivi Ouwerkerk-Mahadevan13, Katleen Callewaert13, William T. Symonds15, Gaston Picchio16, Karen Lindsay16, Maria Beumont-Mauviel13, Eric Lawitz17
1. Weill Cornell Medical College, New York, NY, United States. 2. Medicine and Gastroenterology and Hepatology, The Liver Institute, Dallas, TX, United States. 3. Fundación de Investigación, San Juan, Puerto Rico, United States. 4. Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States. 5. Borland-Groover Clinic, 4800 Belfort Rd, Jacksonville, FL, United States. 6. Johns Hopkins University School of Medicine, Baltimore, MD, United States. 7. Orlando Immunology Center, Orlando, FL, United States. 8. Atlanta Medical Center, Atlanta, GA, United States.
9. University of Pittsburgh Medical Center, Pittsburgh, PA, United States. 10. Atlanta Gastroenterology Association, Atlanta, GA, United States. 11. Yale School of Medicine, New Haven, CT, United States. 12. Scripps Clinic, La Jolla, CA, United States. 13. Janssen Research & Development, Beerse, Belgium. 14. Novellas Healthcare, Zellik, Belgium. 15. Gilead Sciences Inc, Foster City, CA, United States. 16. Janssen Research & Development LLC, Titusville, NJ, United States. 17. The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States.
10
Background • Simeprevir (TMC435) is an investigational, one pill, once-daily,
potent oral HCV NS3/4A protease inhibitor recently approved in Japan and currently under regulatory review in North America and Europe
• Sofosbuvir (GS-7977) is an HCV nucleotide NS5B polymerase inhibitor also currently under regulatory review
• COSMOS is a Phase IIa, randomized, open-label study investigating simeprevir + sofosbuvir +/- ribavirin
• Interim analysisJacobson IM, et al. Abstract #LB-3, AASLD 2013
11
COSMOS: Study design
• Cohort 1: Prior null responders (METAVIR F0-F2)– Final SVR12 for all arms
• Cohort 2: Treatment-naïve and prior null responders (METAVIR F3-F4)– Interim SVR4 for Arms 3 and 4
SMV + SOF + RBV Post-treatment follow-up
0 4 12 24 36 48
Arm 1
Week
SMV + SOF
SMV + SOF + RBV
SMV + SOF
Post-treatment follow-up
Post-treatment follow-up
Post-treatment follow-up
Arm 2
Arm 3
Arm 4
Enrollment ratio 2:1:2:1
N=14
N=24
N=14
N=27
Jacobson IM, et al. Abstract #LB-3, AASLD 2013
12
SMV/ SOF12 Wks
SMV/ SOF/RBV12 Wks
0102030405060708090
100
92 96
7.83.7
24 week treatment
13/14 26/27
SMV/SOF12 wks
SMV/SOF/RBV12 wks
SVR12 (SMV/SOF)
SVR12 (SMV/SOF/RBV)
1/271/14
0102030405060708090
100
93.3 79
16.7
4.2
14/15 19/24
SMV/SOF24 wks
SMV/SOF/RBV 24 wks
Patie
nts
(%)
1/244/24
1/15
Non-virologic failure
Relapse
Cohort 1: Null responders (F0-2)12 week treatment
Jacobson IM, et al. Abstract #LB-3, AASLD 2013
6.7
13
Total Naives Nulls0
102030405060708090
100100 100 10096.3 100
93.3
Patie
nts
(%)
1/27
SVR4 (SMV/SOF)
SVR4 (SMV/SOF/RBV)
12 week treatment
7/7 12/12 7/7 14/15
1/15
Relapse
26/2714/14
Cohort 2: Naïve and prior null responders (F3-4): Interim analysis, SVR4
Jacobson IM, et al. Abstract #LB-3, AASLD 2013
14
Most Common AEs: Cohorts 1 and 2 Combined24 weeks 12 weeks
Patients, n (%) SMV + SOF + RBV (n=54)
SMV + SOF (n=31)
SMV + SOF + RBV (n=54)
SMV + SOF (n=28)
Fatigue 20 (37.0) 10 (32.3) 13 (24.1) 7 (25.0)
Headache 11 (20.4) 7 (22.6) 9 (16.7) 6 (21.4)
Nausea 6 (11.1) 4 (12.9) 8 (14.8) 6 (21.4)
Insomnia 9 (16.7) 2 (6.5) 5 (9.3) 4 (14.3)
Rash 7 (13.0) 3 (9.7) 8 (14.8) 1 (3.6)
Pruritus 9 (16.7) 1 (3.2) 5 (9.3) 3 (10.7)
Photosensitivity/sunburna 2 (3.7) 1 (3.2) 3 (5.6) 2 (7.1)
Anemia 11 (20.4) 1 (3.2) 6 (11.1) 0
aNo sun-protective measures were in place for this trialRBV, ribavirin; SMV, simeprevir; SOF, sofosbuvirJacobson IM, et al. Abstract #LB-3, AASLD 2013
15
• Treatment with SMV + SOF ± RBV results in:– High SVR12 rates in HCV GT 1 null responder patients– High SVR4 rates in naïve and null-responder patients with METAVIR
F3-F4• Addition of RBV to SMV + SOF may not be needed to
achieve high rates of SVR in this patient population• 12 weeks of treatment may confer similar SVR rates
compared with 24 weeks of treatment• SMV + SOF ± RBV was generally well tolerated
Conclusion
Jacobson IM, et al. Abstract #LB-3, AASLD 2013
16
Abstract #73
Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin: the ELECTRON trial
Edward J. Gane1, Catherine A. Stedman2, Robert H. Hyland3, Xiao Ding3, Evguenia S. Svarovskaia3, Phil S. Pang3, William T. Symonds3
1. Auckland Clinical Studies, Auckland, New Zealand. 2. Christchurch Clinical Studies Trust, Christchurch, New Zealand.
3. Gilead Science, Inc, Foster City, CA, United States.
17
Direct Acting Antiviral Agents
GS-9669• HCV NS5B non-nucleoside inhibitor, binding at thumb site II of the polymerase• Potent antiviral activity with QD dosing • Nanomolar potency against GT 1a and 1b
Sofosbuvir/Ledipasvir FDC• Once daily, oral fixed-dose (400/90 mg)
combination tablet• No food effect• >2000 patients treated
SOFNucleotidePolymeraseinhibitor
LDVNS5Ainhibitor
Gane EJ, et al. Abstract #73, AASLD 2013
18
Study Design
• Primary endpoint: SVR12 (HCV RNA <LLOQ)• Patients enrolled in ELECTRON or ELECTRON 2 (GT1, F3/F4)• All groups were open label
GT 1 Experienced
GT 1 Naïve
Wk 0 Wk 6 Wk 12
F4
F3/F4
F0/F1/F2
SOF/LDV FDC (n=10)
SOF/LDV FDC + GS-9669 (n=25)
SOF/LDV FDC + RBV (n=10)
SOF/LDV FDC + RBV (n=25)
SOF/LDV FDC + RBV (n=25)
Ran
dom
ized
Ran
dom
ized SVR12
Gane EJ, et al. Abstract #73, AASLD 2013
19
SVR 12 Results: GT 1 Treatment-Experienced Patients with Advanced Fibrosis/Cirrhosis
SOF/LDV SOF/LDV + RBV0
102030405060708090
100
70
100
SVR
12
(%)
SOF/LDV + RBV SOF/LDV + GS9669
100 100
Duration (wk) 12 12
F4 only F3/F4
12 12
7/10 9/9 25/25* 26/26*
*From ELECTRON 2Gane EJ, et al. Abstract #73, AASLD 2013
20
SVR12 Results: Treatment DurationGenotype 1, Treatment-naïve, No Cirrhosis
SOF + LDV + RBV* SOF/LDV + RBV SOF/LDV + RBV0
102030405060708090
100100 100
68
SVR
12
(%)
*Gane et al. EASL 2013. †Lawitz et al, Abstract #215, AASLD 2013 (LONESTAR)Gane EJ, et al. Abstract #73, AASLD 2013
Duration (wk) 12 8 6
25/25 21/21 17/25
†
21
Conclusions• In treatment-experienced patients with advanced
fibrosis/cirrhosis, either RBV or GS-9669 may enhance the efficacy of SOF/LDV given for 12 weeks
• The optimal duration of SOF/LDV in treatment-naïve GT 1 patients, even with the addition of RBV, is more than 6 weeks
• Regimens of SOF/LDV alone, or with RBV or GS-9669, were safe and well tolerated
Gane EJ, et al. Abstract #73, AASLD 2013
22
Abstract #75
Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naïve Patients and
Prior Null Responders
Eric Lawitz1, Christophe Hezode2, Peter Varunok3, Paul J. Thuluvath4, Tolga Baykal5, Mudra Kapoor5, Sandra S. Lovell5, Tianli Wang5, Tami Pilot-Matias5, Regis A. Vilchez5, Barry Bernstein5
1. The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States.
2. Assistance Publique Hopitaux de Paris, Paris, France. 3. Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, NY, United States.
4. The Institute for Digestive Health and Liver Disease at Mercy, Baltimore, MD, United States. 5. AbbVie Inc., North Chicago, IL, United States.
23
Background and Aims
• ABT-450 is an HCV protease inhibitor (dosed with ritonavir 100 mg, ABT-450/r)
• ABT-267 is an NS5A inhibitor • Both compounds have shown potent antiviral
activity in vitro against HCV genotypes (GT) 1-4 and 6.
Lawitz E, et al. Abstract #75, AASLD 2013
24
PEARL-I Study Design
Substudy 1:PatientsWithoutCirrhosis
Substudy 2:Patients With Compensated Cirrhosis
Group 1 40
Group 2 40
Group 3 40
Group 4 40
Group 5 40
Group 6 40
Group 7 40
Group 8 40
PlannedN
HCV Genotype/RegimenTreatment Experience Week 12 Week 24
GT4 ABT-450/r + ABT-267Treatment-naïveGT1b ABT-450/r + ABT-267Treatment-naïveGT1b ABT-450/r + ABT-267Null RespondersGT4 ABT-450/r + ABT-267 + rbvTreatment-naïveGT4 ABT-450/r + ABT-267Partial/Null Responders & RelapsersGT4 ABT-450/r + ABT-267 + rbvPartial/Null Responders & RelapsersGT1b ABT-450/r + ABT-267Treatment-naïveGT1b ABT-450/r + ABT-267Partial/Null Responders & Relapsers
BL
Lawitz E, et al. Abstract #75, AASLD 2013
25
Efficacy: Treatment-Naïve Patients, ITT
Week 4 Week 12 (EOTR)
SVR4 SVR12
0
20
40
60
80
100P
erce
ntag
e of
Pat
ient
s (%
) 100 97.6
42/42 41/42 41/42 40/42
97.6 95.2
Lawitz E, et al. Abstract #75, AASLD 2013
26
39/40 39/40 37/40
97.597.5 92.5 90.0
36/40
Efficacy: Prior Null Responders, ITT
Week 4 Week 12(EOTR)
SVR4 SVR12
0
20
40
60
80
100P
erce
ntag
e of
Pat
ient
s (%
)
Lawitz E, et al. Abstract #75, AASLD 2013
27
Treatment-Emergent Adverse Events (AEs) Occurring in >10% of Patients in Either Group
Event, n (%)GT1b-infected
Treatment-naïve Patients(N=42)
GT1b-infectedPrior Null Responders
(N=40)
Headache 14 (33.3) 10 (25.0)
Nausea 8 (19.0) 0
Dry Skin 7 (16.7) 0
Fatigue 6 (14.3) 0
Pruritus 6 (14.3) 0
Diarrhea 6 (14.3) 0
Lawitz E, et al. Abstract #75, AASLD 2013
28
Abstract #215
Once Daily Sofosbuvir/Ledipasvir Fixed Dose Combination with or without Ribavirin Resulted in ≥95% Sustained Virologic Response In Patients with HCV Genotype 1, Including Patients
with Cirrhosis: the LONESTAR trial
Eric Lawitz1, Fred Poordad1, Robert H. Hyland2, Xiao Ding2, Christy Hebner2, Phil S. Pang2, William T. Symonds2, John G. McHutchison2, Fernando E. Membreno1
1. The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States.
2. Gilead Science, Inc, Foster City, CA, United States.
29
Study Design
• Single center study of GT 1 patients• Broad inclusion criteria
– No upper limit to age or BMI
– Platelets ≥50,000/mm3
Ran
dom
ized
1:
1
SOF/LDV
SOF/LDV
SOF/LDV + RBV
SOF/LDV
Treatment Naïve
(No
cirrhosis)
PI Failures
(50% cirrhosis) SOF/LDV + RBV
COHORT 1(n=60)
COHORT 2(n=40)
Wk 0 Wk 8 Wk 12
Ran
dom
ized
1:
1:1
Wk 24Wk 20
SVR12
SVR12
SVR12
SVR12
SVR12
Lawitz E, et al. Abstract #215, AASLD 2013
30
Results: Demographics of Patients Who Previously Failed PI Therapy
• All patients were required to have experienced virologic failure– Patients who stopped prior therapy due to an AE were excluded
PI Failuresn=40
Prior treatment with boceprevir 22/40 (55)
Prior treatment with telaprevir 18/40 (45)
Cirrhosis, n (%) 22/40 (55)
Mean platelet count, x 103/µL 107
Mean albumin, g/dL 3.8
Lawitz E, et al. Abstract #215, AASLD 2013
31
SVR12 Results
Series10
20
40
60
80
100 95100 95 95 100
Treatment Naïve(No Cirrhosis)
PI Failures(50% Cirrhosis)
─ ─ ─+ +8 12 128 12
Pat
ient
s (%
)
19/20 21/21 18/19 18/19 21/21
RBVDuration (week)
Lawitz E, et al. Abstract #215, AASLD 2013
32
Patients Who Previously Failed Protease Inhibitor Therapy: With and Without Cirrhosis
Se-ries1
0
20
40
60
80
100 95 100 100 10091
100
No Cirrhosis Cirrhosis
─ +RBV12Duration (week)
Pat
ient
s (%
)
18/19 21/21
Overall
10/10 11/118/8 10/11
12 12─ + ─ +
Lawitz E, et al. Abstract #215, AASLD 2013
33
Results: Safety Summary
Patients, n (%)SOF/LDV
n=58SOF/LDV+RBV
n=42
Overall safety
AEs 24 (41) 24 (57)Grade 3-4 AEs 0 6 (14)Serious AEs 2* (3) 2† (5)Treatment discontinuation due to AEs 0 0
Laboratoryabnormalities
Grade 3-4 laboratory abnormality 4 (7) 6 (14)
Hemoglobin <10 g/dL 0 8 (19)Hemoglobin <8.5 g/dL 0 2 (5)
*Peptic ulcer, spinal compression fracture; †Delirium, suicidal ideation.
Lawitz E, et al. Abstract #215, AASLD 2013
34
Abstract #LB-4
Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment
Experienced Patients with and without Compensated Cirrhosis: Results from the LONESTAR-2 Study
Eric Lawitz1, 2, Fred Poordad1, 2, Diana M. Brainard3, Robert H. Hyland3, Di An3, William T. Symonds3, John G. McHutchison3, Fernando E. Membreno1, 2
1. Texas Liver Institute, San Antonio, TX, United States. 2. University of Texas Health Science Center, San Antonio, TX, United States.
3. Gilead Science, Inc, Foster City, CA, United States.
35
Study Design
SOF + PEG/RBV SVR12GT 2/3(N=47)
• Study population– HCV GT 2 or 3
– Failed treatment with pegylated interferon and ribavirin
– Approximately 50% with compensated cirrhosis
– HIV and HBV coinfected patients excluded
Wk 0 Wk 12 Wk 24 Wk 36
Lawitz E, et al. Abstract #LB-4, AASLD 2013
36
Series10
20
40
60
80
100 89 9683
Results: SVR12 by HCV Genotype
Overall GT 2 GT 342/47 22/23 20/24
SV
R12
(%
)
Lawitz E, et al. Abstract #LB-4, AASLD 2013
37
Results: SVR12 by Cirrhosis Status
GT 2 GT 30
20
40
60
80
100100 8393 83
No Cirrhosis CirrhosisS
VR
12 (%
)
9/9 13/14 10/12 10/12
Error bars represent 95% confidence intervals.
Lawitz E, et al. Abstract #LB-4, AASLD 2013
38
Patients, n (%)SOF + PEG/RBV
12 weeks(N=47)
Overall safety
AEs 45 (96)
Grade 3-4 AEs 15 (32)
Serious AEs 4 (9)
Treatment discontinuation due to AEs 2 (4)
Hematologic abnormalities
Grade 3-4 laboratory abnormality 28 (60)
Hemoglobin <10 g/dL 13 (28)
Hemoglobin <8.5 g/dL 4 (9)
Absolute neutrophil count <750/mm3 13 (28)
Platelets <50,000/mm3 7 (15)
Results: Adverse Events
Lawitz E, et al. Abstract #LB-4, AASLD 2013
39
Conclusions• SOF + PEG/RBV for 12 weeks demonstrated high efficacy
in treatment-experienced GT 2/3 patients who have historically low response rates and limited treatment options
– SVR rates were similar in patients with and without cirrhosis
• SOF + PEG/RBV was generally safe and well tolerated
– Safety profile consistent with PEG/RBV treatment
– Low discontinuation rates
39Lawitz E, et al. Abstract #LB-4, AASLD 2013
40
Abstract #1085
Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patientswith HCV Genotype 2 or 3: the VALENCE trial
Stefan Zeuzem1, Geoffrey M. Dusheiko2, Riina Salupere3, Alessandra Mangia4,Robert Flisiak5, Robert H. Hyland6, Ari Illeperuma6, Evguenia S. Svarovskaia6, Diana M. Brainard6,William T. Symonds6, John G. McHutchison6, Ola Weiland7, Hendrik W. Reesink8, Peter Ferenci9,
Christophe Hezode10, Rafael Esteban11
1. Johann Wolfgang Goethe University, Frankfurt, Germany.
2. Royal Free and University College School of Medicine, Royal Free Hospital, London, United Kingdom. 3. Tartu University Hospital, Tartu, Estonia. 4. "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo, Italy. 5. Medical University of Bialystok, Bialystok, Poland. 6. Gilead Sciences, Inc., Foster City, CA, United States.
7. Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. 8. Academic Medical Center, Amsterdam, Netherlands. 9. Medical University of Vienna, Vienna, Austria. 10. Hôpital Henri Mondor, Créteil, France. 11. Hospital Universitario Val d’Hebron, Barcelona, Spain.
41
Wk 0 Wk 24 SVR4, SVR12, SVR24
Placebo*(n = 85)
Sofosbuvir + Ribavirin (n = 250)
Sofosbuvir + Ribavirin(n = 84)*
*Protocol amended to eliminate placebo arm and to extend treatment duration to 24 weeks for patients with genotype 3 HCV irrespective of prior treatment history.
VALENCE: Study Design
Wk 12
Zeuzem S, et al. Abstract #1085, AASLD 2013
42
0
20
40
60
80
100 97 10091 88
SVR12 in GT 2 Patients Treated for 12 Weeks
SVR
12 (%
)
*3 of 11 patients (27%) with HCV GT 3 who received 12 weeks of SOF+RBV achieved SVR 12.Zeuzem S, et al. Abstract #1085, AASLD 2013
0
20
40
60
80
100 9385
SVR12 in GT 2 and 3 Patients*
SVR
12 (%
)
GT 2SOF+RBV 12 wk
GT 3SOF+RBV 24 wk
Naïve,Noncirrhotic
Naïve,Cirrhotic
Experienced,Noncirrhotic
Experienced,Cirrhotic
68/73212/250 29/30 2/2 30/33 7/8
43
SVR12 in GT 3 Patients Treated for 24 Weeks
0
20
40
60
80
100 94 9287
60
SVR
12 (%
)
Naïve,Noncirrhotic
Naïve,Cirrhotic
Experienced,Noncirrhotic
Experienced,Cirrhotic
86/92 12/13 27/4587/100
Zeuzem S, et al. Abstract #1085, AASLD 2013
44
Abstract #LB-2
Sofosbuvir and Ribavirin for the Treatment of Established Recurrent Hepatitis C Infection After Liver Transplantation:
Preliminary Results of a Prospective, Multicenter Study
1. Mayo Clinic, Rochester, MN, United States. 2. Auckland City Hospital, Auckland, New Zealand. 3. Hannover Medical School, Hannover, Germany. 4. Columbia University, New York, NY, United States. 5. Beth Israel Deaconess Medical Center, Boston, MA, United States. 6. Indiana School of Medicine, Indianapolis, IN, United States. 7. University of Michigan, Ann Arbor, MI, United States.
8. Kansas University Medical Center, Lawrence, KS, United States. 9. NYU Medical Center, New York , NY, United States. 10. Duke University Medical Center, Durham, NC, United States. 11. Gilead Sciences, Foster City, CA, United States. 12. University of California, San Francisco, CA, United States. 13. Université Paris-Sud, Villejuif, France. 14. The Liver Unit, Barcelona, Spain.
Michael R. Charlton1, Edward J. Gane2, Michael P. Manns3, Robert S. Brown4, Michael P. Curry5,Paul Y. Kwo6, Robert J. Fontana7, Richard Gilroy8, Lewis W. Teperman9, Andrew J. Muir10,
John G. McHutchison11, William T. Symonds11, Jill M. Denning11, Lindsay McNair11, Sarah Arterburn11,Norah Terrault12, Didier Samuel13, Xavier Forns14
45
Background• Reinfection of the transplanted liver is universal in patients who are serum
HCV RNA-positive at the time of transplantation• Recurrence of HCV is the most common cause of mortality and graft loss
following transplantation– 10–50% of patients with recurrent infection progress to cirrhosis within 5 years1
• Once cirrhosis is established, the probability of liver graft failure is 42% within 12 months2
• Current therapies for HCV treatment used after transplantation have poor tolerance, poor efficacy, severe adverse reactions, and significant interactions with immunosuppression medications
1. Berenguer M, et al. Clin Liver Dis 2007;11:355–76; 2. Berenguer M, et al. Hepatology 2002;36:202-10. Charlton MR, et al. Abstract #LB-2, AASLD 2013
46
Study Design and Objectives
• Patients with recurrent HCV post-liver transplant, all genotypes
• Low, ascending-dose RBV regimen starting at 400 mg/day, escalated based on hemoglobin levels
• Study objectives– Primary: sustained virologic response 12 weeks post treatment with
sofosbuvir + RBV in liver transplant recipients – Secondary: safety, tolerability and viral kinetics
SOF 400 mg + RBV 400‒1200 mg (N=40) SVR12
Week 0 12 24 36
Charlton MR, et al. Abstract #LB-2, AASLD 2013
47
Key Inclusion/Exclusion Criteria• Inclusion criteria
– Liver transplant ≥6 and ≤150 months prior to enrollment– Treatment-naïve or experienced– CPT ≤7 and MELD ≤17– Primary or secondary, liver alone or liver-kidney transplant – Absence of organ rejection
• Exclusion criteria– Current signs of decompensation– Use of corticosteriods at any dose >5 mg of prednisone/day
Charlton MR, et al. Abstract #LB-2, AASLD 2013
48
Results: Virologic Response
Week 4 EOT* SVR 40
20
40
60
80
100100 100
77
39/3940/40 27/35†Viro
logi
c R
espo
nse
Rat
e (%
)
*1 patient still on treatment; †4 patients have not reached SVR4 visit.Charlton MR, et al. Abstract #LB-2, AASLD 2013
49
Concomitant Immunosuppression
• No interactions reported between SOF and any immunosuppressive agents during study• 4 patients increased tacrolimus dosing during SOF therapy
0
20
40
60
80
100
70
3528 25
511/4028/40 14/40 10/40 2/40
Tacrolimus Mycophenolate mofetil
Prednisone Cyclosporin Azathioprine
Pat
ient
s (%
)
Charlton MR, et al. Abstract #LB-2, AASLD 2013
50
Grade 3 and 4 Laboratory Abnormalities
n (%)SOF + RBV
N=40
Overall Grade 3 10 (25)Overall Grade 4 11 (28)Lymphocytes (4 G3; 9 G4) 13 (33)Hemoglobin (G3) 8 (20)Hyperglycemia (3 G3; 1 G4) 4 (10)White blood count (G3) 3 (8)Hyperbilirubinemia (G4) 1 (3)Lipase (G4) 1 (3)Neutrophil (G3) 1 (3)AST (G3) 1 (3)
Charlton MR, et al. Abstract #LB-2, AASLD 2013
51
Abstract #213
Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection after Liver Transplantation
Michael P. Curry1, Xavier Forns2, Raymond T. Chung3, Norah Terrault4, Robert S. Brown5, Jonathan M. Fenkel6, Fredric D. Gordon7, Jacqueline G. O'Leary8, Alexander Kuo9, Thomas D. Schiano10, Gregory T.
Everson11, Eugene R. Schiff12, Alex Befeler13, John G. McHutchison14, William T. Symonds14, Jill M. Denning14, Lindsay McNair14, Sarah Arterburn14, Dilip Moonka15, Edward J. Gane16, Nezam H. Afdhal1
1. Beth Israel Deaconess Medical Center, Boston, MA, United States. 2. The Liver Unit, Barcelona, Spain. 3. Massachusetts General Hospital, Boston, MA, United States. 4. University of California San Francisco, San Francisco, CA, United States. 5. Columbia University, New York, NY, United States. 6. Thomas Jefferson University Hospital, Philadelphia, PA, United States. 7. Lahey Clinic, Burlington, MA, United States. 8. Baylor University Medical Center, Dallas, TX, United States.
9. University of California San Diego, La Jolla, CA, United States. 10. Mount Sinai School of Medicine, New York, NY, United States. 11. University of Colorado, Denver, CO, United States. 12. University of Miami, Miami, FL, United States. 13. St. Louis University, St. Louis, MO, United States. 14. Gilead Sciences, Foster City, CA, United States. 15. Henry Ford Health System, Detroit, MI, United States. 16. Auckland City Hospital, Auckland, New Zealand.
52
Background and Aims:
• Recurrent HCV infection of the allograft is universal in patients with detectable HCV RNA at the time of liver transplantation (LT) and may result in accelerated progression to cirrhosis and graft loss.
• Interferon-based antiviral treatment before LT can prevent HCV recurrence, but this treatment is poorly tolerated and effective in only a minority of patients.
Curry MP, et al. Abstract #213, AASLD 2013
53
Methods: • In this phase 2 open-label study, patients with chronic HCV infection of any
genotype (GT) listed for LT for hepatocellular carcinoma (HCC) received up to 48 weeks of SOF 400 mg/day and RBV 1000-1200 mg/day before LT.
• All patients had HCC within Milan criteria and well compensated cirrhosis (Child-Pugh-Turcotte score of ≤7).
• The primary endpoint was virologic response (HCV RNA <25 IU/mL) 12 weeks after LT in patients who had HCV RNA <25 IU/mL at their last measurement prior to LT (SVR12).
• Post-LT immunosuppressive regimen was tacrolimus plus prednisone with or without mycophenolate mofetil.
Curry MP, et al. Abstract #213, AASLD 2013
54
Results: • 36 patients included in efficacy analysis
• Received a mean of 17.1 (range 3.3 to 33.7) weeks of treatment prior to LT
• At the time of writing, 26 patients have reached at least 12 weeks post-transplant, of whom 18 (69%, 90% CI 51% to 84%) achieved SVR12.
• The most frequently reported adverse events were fatigue, anemia, and rash.
• Two patients discontinued treatment due to AEs of acute renal failure and pneumonitis, neither was attributed to study drug.
• One SAE, anemia, was considered related to study drug. Curry MP, et al. Abstract #213, AASLD 2013